[{"address1": "4 Kingsbury Avenue", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 607 0800", "fax": "617 607 0530", "website": "https://www.enanta.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 120, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay R. Luly Ph.D.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1231428, "exercisedValue": 0, "unexercisedValue": 67815}, {"maxAge": 1, "name": "Dr. Yat Sun Or Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 740108, "exercisedValue": 0, "unexercisedValue": 22091}, {"maxAge": 1, "name": "Mr. Matthew P. Kowalsky J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 575652, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott T. Rottinghaus M.D.", "age": 50, "title": "Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 776138, "exercisedValue": 43483, "unexercisedValue": 14728}, {"maxAge": 1, "name": "Mr. Harry R. Trout III", "age": 55, "title": "Interim Principal Financial Officer", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kathleen S. Capps CPA", "age": 40, "title": "Interim Principal Accounting Officer", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Viera", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathaniel S. Gardiner J.D.", "age": 70, "title": "Consultant", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 672675, "exercisedValue": 49136, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tara Lynn Kieffer Ph.D.", "age": 46, "title": "Chief Product Strategy Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 496852, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan  Luu", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 622856, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 6, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 14.53, "open": 14.58, "dayLow": 14.42, "dayHigh": 15.86, "regularMarketPreviousClose": 14.53, "regularMarketOpen": 14.58, "regularMarketDayLow": 14.42, "regularMarketDayHigh": 15.86, "payoutRatio": 0.0, "beta": 0.972, "forwardPE": -6.151079, "volume": 1291019, "regularMarketVolume": 1291019, "averageVolume": 755171, "averageVolume10days": 298930, "averageDailyVolume10Day": 298930, "bid": 14.14, "ask": 15.43, "bidSize": 1, "askSize": 1, "marketCap": 444046496, "fiftyTwoWeekLow": 4.09, "fiftyTwoWeekHigh": 15.86, "allTimeHigh": 127.77, "allTimeLow": 4.09, "priceToSalesTrailing12Months": 6.797601, "fiftyDayAverage": 12.3789, "twoHundredDayAverage": 8.420425, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 456387424, "profitMargins": -1.25358, "floatShares": 21863709, "sharesOutstanding": 28852923, "sharesShort": 2480681, "sharesShortPriorMonth": 2734788, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.0859, "heldPercentInsiders": 0.04897, "heldPercentInstitutions": 0.71266, "shortRatio": 6.7, "shortPercentOfFloat": 0.089899994, "impliedSharesOutstanding": 28852924, "bookValue": 3.026, "priceToBook": 5.0859222, "lastFiscalYearEnd": 1759190400, "nextFiscalYearEnd": 1790726400, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -81889000, "trailingEps": -3.84, "forwardEps": -2.502, "enterpriseToRevenue": 6.987, "enterpriseToEbitda": -5.651, "52WeekChange": 1.2810047, "SandP52WeekChange": 0.1340276, "quoteType": "EQUITY", "currentPrice": 15.39, "targetHighPrice": 28.0, "targetLowPrice": 11.0, "targetMeanPrice": 19.125, "targetMedianPrice": 20.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 188864000, "totalCashPerShare": 6.544, "ebitda": -80763000, "totalDebt": 201056000, "quickRatio": 4.031, "currentRatio": 4.208, "totalRevenue": 65324000, "debtToEquity": 310.67, "revenuePerShare": 3.062, "returnOnAssets": -0.16229, "returnOnEquity": -0.84626, "grossProfits": 65324000, "freeCashflow": -18544750, "operatingCashflow": -19272000, "revenueGrowth": 0.035, "grossMargins": 1.0, "ebitdaMargins": -1.23634, "operatingMargins": -1.2156, "financialCurrency": "USD", "symbol": "ENTA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Enanta Pharmaceuticals, Inc.", "longName": "Enanta Pharmaceuticals, Inc.", "regularMarketChangePercent": 5.91879, "regularMarketPrice": 15.39, "postMarketPrice": 15.57, "postMarketChange": 0.17999935, "regularMarketChange": 0.860001, "regularMarketDayRange": "14.42 - 15.86", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 755171, "fiftyTwoWeekLowChange": 11.3, "fiftyTwoWeekLowChangePercent": 2.7628362, "fiftyTwoWeekRange": "4.09 - 15.86", "fiftyTwoWeekHighChange": -0.4699993, "fiftyTwoWeekHighChangePercent": -0.029634258, "fiftyTwoWeekChangePercent": 128.10046, "corporateActions": [], "postMarketTime": 1766191092, "regularMarketTime": 1766178001, "exchange": "NMS", "messageBoardId": "finmb_345286", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "earningsTimestamp": 1763413200, "earningsTimestampStart": 1770670800, "earningsTimestampEnd": 1770670800, "earningsCallTimestampStart": 1715027400, "earningsCallTimestampEnd": 1715027400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.84, "epsForward": -2.502, "epsCurrentYear": -3.06625, "priceEpsCurrentYear": -5.0191603, "fiftyDayAverageChange": 3.0111008, "fiftyDayAverageChangePercent": 0.24324462, "twoHundredDayAverageChange": 6.969575, "twoHundredDayAverageChangePercent": 0.82769865, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1363872600000, "postMarketChangePercent": 1.1695864, "displayName": "Enanta Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]